The FDA granted orphan drug designation to AVS100 for the treatment of stage IIB through stage IV melanoma, according to the agent’s manufacturer.
2022
Melanoma Maneuvers Mortality by Maintaining Telomeres
It may appear counter-intuitive but overcoming death is a key step in the journey of a cell toward cancer.
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA Melanoma
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab (Opdivo), according to a real-world analysis presented at the 19th International Congress of the Society for Melanoma Research.
MGH Researchers Develop AI Tool To Predict Melanoma Recurrence
A team of scientists at Massachusetts General Hospital has developed a new tool that uses artificial intelligence to predict which patients are most likely to experience a recurrence of melanoma, the most deadly form of skin cancer.